Skip to main content
. Author manuscript; available in PMC: 2023 Mar 1.
Published in final edited form as: Neuropharmacology. 2021 Nov 29;205:108907. doi: 10.1016/j.neuropharm.2021.108907

Figure 9. Six weeks of pioglitazone does not change heat hypersensitivity in db/db mice.

Figure 9.

Pioglitazone did not change heat hypersensitivity in (A) male or (B) female db/db mice. (C) Analysis of the data with Time collapsed across post-injection timepoints illustrates that pioglitazone did not change heat hypersensitivity. Pioglitazone decreased food consumption in (D) males and (E) female mice. (F) Analysis of the data with Time collapsed across post-injection timepoints illustrates that the 30 mg/kg/day dose of pioglitazone decreased food consumption in females. Pioglitazone significantly increased body weight in (G) males but not (H) females. (I) Pioglitazone 30 mg/kg/d increased body weight (change from 13 to 20 weeks of age) to a greater extent in males as compared to females. Pioglitazone decreased non-fasting glucose levels in (J) males but not females (K). (L) Pioglitazone 30 mg/kg/d increased HbA1c (change from 13 to 20 weeks of age) in males but not females. 30 mg/kg/d produced greater increases in males. Two-way ANOVA was performed followed by Sidak’s multiple comparisons test for figures 9A–B, 9D–E, G–H and J–k. Tukey’s multiple comparisons test was performed for figure 9C, F, I and L. *p<0.05, **p<0.01. Values = mean ± SEM. N=5–6.